Trial Profile
Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Acronyms FLU-D-PAN-H1N1-021
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 29 Dec 2010 Actual end date (1 Aug 2010) added as reported by ClinicalTrials.gov.
- 29 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2009 Preliminary results from an interim analysis of the seroconversion and seroprotection rates have been published in the journal Vaccines.